Carl A Harrell

US Patent:

20120189586, Jul 26, 2012

Filed:

Jan 20, 2012

Appl. No.:

13/354964

Inventors:

Carl Randall Harrell - Tarpon Springs FL, US

International Classification:

A61K 35/12
A61P 43/00
A61K 38/39

US Classification:

424 937, 514 172

Abstract:

The invention provides a composition for use in tissue augmentation of a human. More specifically, the composition comprises collagen extracted from human placenta and a bulking agent. Furthermore, the invention discloses methods of augmenting soft tissue comprising the use of the compositions described herein.

US Patent:

20130245528, Sep 19, 2013

Filed:

Mar 13, 2013

Appl. No.:

13/798742

Inventors:

Carl Randall Harrell - Tarpon Springs FL, US

International Classification:

A61K 9/00

US Classification:

602 50, 604367, 514 172, 424400, 424 946, 424 937, 514 136, 514 82, 514 96, 514 89, 514 86, 514 59

Abstract:

Provided herein is a topical wound dressing that comprises a collagen and a flexible paste. Also provided is a wound dressing with a first layer of a sterilized mixture of collagen and a second adhesive layer effective to adhere to surrounding skin and to keep the first layer in contact with the wound. In addition there is provided a wound dressing foil that comprises collagen and a plastic compound that can provide a foil shape. Furthermore, methods of dressing wounds utilizing the wound dressings and wound dressing foil are provided herein.

US Patent:

20220184141, Jun 16, 2022

Filed:

Mar 8, 2022

Appl. No.:

17/654038

Inventors:

- Tarpon Springs FL, US
Carl Randall Harrell - Tarpon Springs FL, US

International Classification:

A61K 35/50
A61K 9/14
A61K 9/00
A61L 31/16
A61L 31/00
A61L 27/54
A61L 27/36
A61P 19/02
A61P 19/00
A61K 38/18
A61P 19/10

Abstract:

A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration, or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on the severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft tissues.

US Patent:

20230021477, Jan 26, 2023

Filed:

Sep 19, 2022

Appl. No.:

17/933374

Inventors:

- Tarpon Springs FL, US
Carl Randall Harrell - Tarpon Springs FL, US

International Classification:

A61K 35/50
A61K 45/06
A61P 11/06
A61P 11/00
A61H 23/02
A61K 9/00

Abstract:

Formulations of human amniotic fluid and methods of use thereof for treatment of chronic lung disorders have been developed. The formulations are suitable for topical delivery to the lung, for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-I antitrypsin emphysema. Methods including administering specifically formulated, diluted sterile decellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder

US Patent:

20210060084, Mar 4, 2021

Filed:

Aug 21, 2020

Appl. No.:

16/999259

Inventors:

- Tarpon Springs FL, US
Carl Randall Harrell - Tarpon Springs FL, US

International Classification:

A61K 35/50
A61P 37/06

Abstract:

Compositions and formulations of de-cellularized human amniotic fluid (D-HAF) and methods of use thereof are described. The compositions and formulations typically including over 300 human growth factors and stem cell derived exosomes can be used for therapeutic immunosuppression strategies useful in the treatment of inflammatory diseases or disorders, autoimmune diseases or disorders, inducing or increase graft tolerance, treating graft rejection, and treating allergies and other ailments particularly those involving eyes, joints, and the respiratory system with symptoms that can be reduced or ameliorated by regulating the activity of T cells (Th1, Th2, Th17, and/or Tregs), NK cells, antigen-presenting cells, or combinations thereof. Compositions and methods for balancing a T-helper cell profile and in particular for suppressing or reducing expansion of inflammatory Th1 and Th17 cells and/or promoting generation of immunosuppressive Tregs are provided.

US Patent:

20200077987, Mar 12, 2020

Filed:

Nov 14, 2019

Appl. No.:

16/683939

Inventors:

- Tarpon Springs FL, US
Carl Randall Harrell - Tarpon Springs FL, US

International Classification:

A61B 10/00
A61B 8/08
A61L 2/08
A61M 1/00

Abstract:

Provided herein is a pre-Caesarean method for collecting amniotic fluid from a patient. A needle is inserted into the incision site for the future C-section, which may be under ultrasound guidance, through which the amniotic fluid is drawn under a low level suction and, optionally, gravity to a sterile collection container. The method encompasses filtering and/or irradiating the amniotic fluid to collect biomolecules of interest such as growth factors and/or stem cells. Also provided is the sterile amniotic fluid or filtrates thereof collected by the method described herein

US Patent:

20190015548, Jan 17, 2019

Filed:

Jul 12, 2018

Appl. No.:

16/033803

Inventors:

- Tarpon Springs FL, US
Carl Randall Harrell - Tarpon Springs FL, US

International Classification:

A61L 27/24
A61K 38/39
A61L 27/54
A61K 45/06
A61L 27/36
A61L 27/60
A61L 27/38
A61K 35/50

Abstract:

Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

US Patent:

20180311284, Nov 1, 2018

Filed:

Jun 29, 2018

Appl. No.:

16/023041

Inventors:

- Tarpon Springs FL, US
Carl Randall Harrell - Tarpon Springs FL, US

International Classification:

A61K 35/50
A61K 9/19
A61K 9/08
A61K 9/00

Abstract:

A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.